About: Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID‐19 pandemic: The Princess Margaret experience and proposal

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID‐19 pandemic: The Princess Margaret experience and proposal Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID‐19 pandemic: The Princess Margaret experience and proposal
Creator	Xu, Wei Kim, John Huang, Shao Bayley, Andrew Bratman, Scott Cho, John De Almeida, John Giuliani, Meredith Goldstein, David Hope, Andrew Hosni, Ali Irish, Jonathan O'sullivan, Brian Ringash, Jolie Siu, Lillian Spreafico, Anna Waldron, John Gilbert, Ralph Hansen, Aaron Su, Jie Tong, Li
Source	Medline; PMC
abstract	BACKGROUND: The objective of this study was to identify a subgroup of patients with head and neck squamous cell carcinoma (HNSCC) who might be suitable for hypofractionated radiotherapy (RT‐hypo) during the COVID‐19 pandemic. METHODS: HNSCC cases (oropharynx/larynx/hypopharynx) treated with definitive RT‐hypo (60 Gy in 25 fractions over 5 weeks), moderately accelerated radiotherapy (RT‐acc) alone (70 Gy in 35 fractions over 6 weeks), or concurrent chemoradiotherapy (CCRT) during 2005‐2017 were included. Locoregional control (LRC) and distant control (DC) after RT‐hypo, RT‐acc, and CCRT were compared for various subgroups. RESULTS: The study identified 994 human papillomavirus–positive (HPV+) oropharyngeal squamous cell carcinoma cases (with 61, 254, and 679 receiving RT‐hypo, RT‐acc, and CCRT, respectively) and 1045 HPV– HNSCC cases (with 263, 451, and 331 receiving RT‐hypo, RT‐acc, and CCRT, respectively). The CCRT cohort had higher T/N categories, whereas the radiotherapy‐alone patients were older. The median follow‐up was 4.6 years. RT‐hypo, RT‐acc, and CCRT produced comparable 3‐year LRC and DC for HPV+ T1‐2N0‐N2a disease (seventh edition of the TNM system [TNM‐7]; LRC, 94%, 100%, and 94%; P = .769; DC, 94%, 100%, and 94%; P = .272), T1‐T2N2b disease (LRC, 90%, 94%, and 97%; P = .445; DC, 100%, 96%, and 95%; P = .697), and T1‐2N2c/T3N0‐N2c disease (LRC, 89%, 93%, and 95%; P = .494; DC, 89%, 90%, and 87%; P = .838). Although LRC was also similar for T4/N3 disease (78%, 84%, and 88%; P = .677), DC was significantly lower with RT‐hypo or RT‐acc versus CCRT (67%, 65%, and 87%; P = .005). For HPV– HNSCC, 3‐year LRC and DC were similar with RT‐hypo, RT‐acc, and CCRT in stages I and II (LRC, 85%, 89%, and 100%; P = .320; DC, 99%, 98%, and 100%; P = .446); however, RT‐hypo and RT‐acc had significantly lower LRC in stage III (76%, 69%, and 91%; P = .006), whereas DC rates were similar (92%, 85%, and 90%; P = .410). Lower LRC in stage III predominated in patients with laryngeal squamous cell carcinoma receiving RT‐acc (62%) but not RT‐hypo (80%) or CCRT (92%; RT‐hypo vs CCRT: P = .270; RT‐acc vs CCRT: P = .004). CCRT had numerically higher LRC in comparison with RT‐hypo or RT‐acc in stage IV (73%, 65%, and 66%; P = .336). CONCLUSIONS: It is proposed that RT‐hypo be considered in place of CCRT for HPV+ T1‐T3N0‐N2c (TNM‐7) HNSCCs, HPV– T1‐T2N0 HNSCCs, and select stage III HNSCCs during the COVID‐19 outbreak.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1002/cncr.32968
bibo:pmid	32478895
has license	no-cc
sha1sum (hex)	aabf0d4edaadb870a0c2acc1de74569b561650d5
schema:url	https://doi.org/10.1002/cncr.32968
resource representing a document's title	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID‐19 pandemic: The Princess Margaret experience and proposal
has PubMed Central identifier	PMC7300809
has PubMed identifier	32478895
schema:publication	Cancer
resource representing a document's body	covid:aabf0d4edaadb870a0c2acc1de74569b561650d5#body_text
is schema:about of	named entity 'DISTANT' named entity '2860' named entity 'CONTROL' named entity 'COVID-19 PANDEMIC' named entity 'VARIOUS' named entity 'HYPO' named entity 'LOCOREGIONAL CONTROL' named entity 'HEAD AND NECK SQUAMOUS CELL CARCINOMA' named entity 'radiotherapy' named entity 'HNSCC' named entity 'HNSCC' named entity 'larynx' named entity 'radiotherapy' named entity 'chemoradiotherapy' named entity 'hypopharynx' named entity 'Head and Neck Cancer' named entity 'HNSCC' named entity 'stage II' named entity 'fractionation' named entity 'fractionation' named entity 'stage III' named entity 'HPV' named entity 'Stage III' named entity '95% CI' named entity 'infection' named entity 'HNSCC' named entity 'Head and neck' named entity 'edema' named entity 'cohort study' named entity 'HPV testing' named entity 'median follow-up' named entity 'HPV' named entity 'sample sizes' named entity 'HNSCC' named entity 'HPV' named entity 'computed tomography' named entity 'chemotherapy' named entity 'chemotherapy' named entity 'sample sizes' named entity 'primary tumors' named entity 'selection bias' named entity 'COVID' named entity 'HNC' named entity 'tumor biology' named entity 'stage III' named entity 'metastasis' named entity 'TNM' named entity 'HNSCC' named entity 'radiation dose' named entity 'radiotherapy' named entity 'COVID' named entity 'HPV' named entity 'thyroid cartilage' named entity 'immunosuppressive' named entity 'surgical oncologist' named entity 'peer-reviewed' named entity 'tumor' named entity 'HNSCC' named entity 'tumors' named entity 'Radiation Therapy Oncology Group' named entity 'chemotherapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software